FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384131508> ?p ?o ?g. }

• W4384131508 abstract "Malaria continues to be a burden globally with a myriad of challenges deterring eradication efforts. With most antimalarials facing drug resistance, such as atovaquone (ATQ), alternative compounds that can withstand resistance are warranted. The Plasmodium falciparum cytochrome b (PfCytb), a subunit of P. falciparum cytochrome bc1 complex, is a validated drug target. Structurally, cytochrome b, cytochrome c1, and iron sulphur protein (ISP) subunits form the catalytic domain of the protein complex having heme bL, heme bH and iron-sulphur [2FE-2S] cluster cofactors. These cofactos have redox centres to aid in the electron transfer (ET) process. These subunits promote ET mainly through the enzyme’s ubiquinol oxidation (Qo) and ubiquinone reduction (Qi) processes in the catalytic domain. ATQ drug has been used in the prevention and treatment of uncomplicated malaria by targeting PfCytb protein. Once the mitochondrial transmembrane ET pathway is inhibited, it causes a collapse in its membrane potential. Previously reported ATQ drug resistance has been associated with the point mutations Y268C, Y268N and Y268S. Thus, in finding alternatives to the ATQ drug, this research aimed to: i) employ in silico approaches incorporating protein into phospholipid bilayer for the first time to understand the parasites’ resistance mechanism; ii) determine any sequence and structural differences that could be explored in drug design studies; and iii) screen for PfCytb-iron sulphur protein (Cytb-ISP) hit compounds from South African natural compound database (SANCDB) and Medicines for Malaria Venture (MMV) that can withstand the identified mutations. Using computational tools, comparative sequence and structural analyses were performed on the cytochrome b protein, where the ultimate focus was on P. falciparum cytochrome b and its human homolog. Through multiple sequence alignment, motif discovery and phylogeny, differences between P. falciparum and H. sapiens cytochrome b were identified. Protein modelling of both P. falciparum and H. sapiens cytochrome b - iron sulphur protein (PfCytb-ISP and HsCytb-ISP) was performed. Results showed that at the sequence level, there were few amino acid residue differences because the protein is highly conserved. Important to note is the four-residue deletion in Plasmodium spp. absent in the human homolog. Motif analysis discovered five unique motifs in P. falciparum cytochrome b protein which were mapped onto the predicted protein model. These motifs were not in regions of functional importance; hence their function is still unknown. At a structural level, the four-residue deletion was observed to alter the Qo substrate binding pocket as reported in previous studies and confirmed in this study. This deletion resulted in a 0.83 Å structural displacement. Also, there are currently no in silico studies that have performed experiments with P. falciparum cytochrome b protein incorporated into a phospholipid bilayer. Using 350 ns molecular dynamics (MD) simulations of the holo and ATQ-bound systems, the study highlighted the resistance mechanism of the parasite protein where the loss of active site residue-residue interactions was identified, all linked to the three mutations. The identified compromised interactions are likely to destabilise the protein’s function, specifically in the Qo substrate binding site. This showed the possible effect of mutations on ATQ drug activity, where all three mutations were reported to share a similar resistance mechanism. Thereafter, this research work utilised in silico approaches where both Qo active site and interface pocket were targeted by screening the South African natural compounds database (SANCDB) and Medicines for Malaria Venture (MMV) compounds to identify novel selective hits. SANCDB compounds are known for their structural complexity that preserves the potency of the drug molecule. Both SANCDB and MMV compounds have not been explored as inhibitors against the PfCytb drug target. Molecular docking, molecular dynamics (MD) simulations, principal component, and dynamic residue network (DRN; global and local) analyses were utilised to identify and confirm the potential selective inhibitors. Docking results identified compounds that bound selectively onto PfCytb-ISP with a binding energy ≤ -8.7 kcal/mol-1. Further, this work validated a total of eight potential selective compounds to inhibit PfCytb-ISP protein (Qo active site) not only in the wild-type but also in the presence of the point mutations Y268C, Y268N and Y268S. The selective binding of these hit compounds could be linked to the differences reported at sequence/residue level in chapter 3. DRN and residue contact map analyses of the eight compounds in holo and ligand-bound systems revealed reduced residue interactions and decreased protein communication. This suggests that the eight compounds show the possibility of inhibiting the parasite and disrupting important residue-residue interactions. Additionally, 13 selective compounds were identified to bind at the protein’s heterodimer interface, where global and local analysis confirmed their effect on active site residues (distal location) as well as on the communication network. Based on the sequence differences between PfCytb and the human homolog, these findings suggest these selective compounds as potential allosteric modulators of the parasite enzyme, which may serve as possible replacements of the already resistant ATQ drug. Therefore, these findings pave the way for further in vitro studies to establish their anti-plasmodial inhibition levels." @default.
• W4384131508 created "2023-07-14" @default.
• W4384131508 creator A5079738566 @default.
• W4384131508 date "2023-07-13" @default.
• W4384131508 modified "2023-09-24" @default.
• W4384131508 title "Identification of novel compounds against Plasmodium falciparum Cytochrome bc1 Complex inhibiting the trans-membrane electron transfer pathway : an In Silico study" @default.
• W4384131508 doi "https://doi.org/10.21504/10962/365666" @default.
• W4384131508 hasPublicationYear "2023" @default.
• W4384131508 type Work @default.
• W4384131508 citedByCount "0" @default.
• W4384131508 crossrefType "dissertation" @default.
• W4384131508 hasAuthorship W4384131508A5079738566 @default.
• W4384131508 hasBestOaLocation W43841315081 @default.
• W4384131508 hasConcept C104292427 @default.
• W4384131508 hasConcept C104317684 @default.
• W4384131508 hasConcept C118892022 @default.
• W4384131508 hasConcept C14471203 @default.
• W4384131508 hasConcept C148292235 @default.
• W4384131508 hasConcept C181199279 @default.
• W4384131508 hasConcept C185592680 @default.
• W4384131508 hasConcept C203014093 @default.
• W4384131508 hasConcept C24586158 @default.
• W4384131508 hasConcept C2775905019 @default.
• W4384131508 hasConcept C2776217839 @default.
• W4384131508 hasConcept C2778048844 @default.
• W4384131508 hasConcept C2778371730 @default.
• W4384131508 hasConcept C2779124865 @default.
• W4384131508 hasConcept C2780768313 @default.
• W4384131508 hasConcept C28859421 @default.
• W4384131508 hasConcept C29311851 @default.
• W4384131508 hasConcept C515207424 @default.
• W4384131508 hasConcept C55493867 @default.
• W4384131508 hasConcept C82880906 @default.
• W4384131508 hasConcept C86803240 @default.
• W4384131508 hasConceptScore W4384131508C104292427 @default.
• W4384131508 hasConceptScore W4384131508C104317684 @default.
• W4384131508 hasConceptScore W4384131508C118892022 @default.
• W4384131508 hasConceptScore W4384131508C14471203 @default.
• W4384131508 hasConceptScore W4384131508C148292235 @default.
• W4384131508 hasConceptScore W4384131508C181199279 @default.
• W4384131508 hasConceptScore W4384131508C185592680 @default.
• W4384131508 hasConceptScore W4384131508C203014093 @default.
• W4384131508 hasConceptScore W4384131508C24586158 @default.
• W4384131508 hasConceptScore W4384131508C2775905019 @default.
• W4384131508 hasConceptScore W4384131508C2776217839 @default.
• W4384131508 hasConceptScore W4384131508C2778048844 @default.
• W4384131508 hasConceptScore W4384131508C2778371730 @default.
• W4384131508 hasConceptScore W4384131508C2779124865 @default.
• W4384131508 hasConceptScore W4384131508C2780768313 @default.
• W4384131508 hasConceptScore W4384131508C28859421 @default.
• W4384131508 hasConceptScore W4384131508C29311851 @default.
• W4384131508 hasConceptScore W4384131508C515207424 @default.
• W4384131508 hasConceptScore W4384131508C55493867 @default.
• W4384131508 hasConceptScore W4384131508C82880906 @default.
• W4384131508 hasConceptScore W4384131508C86803240 @default.
• W4384131508 hasLocation W43841315081 @default.
• W4384131508 hasOpenAccess W4384131508 @default.
• W4384131508 hasPrimaryLocation W43841315081 @default.
• W4384131508 hasRelatedWork W1501456700 @default.
• W4384131508 hasRelatedWork W1773260659 @default.
• W4384131508 hasRelatedWork W1972977875 @default.
• W4384131508 hasRelatedWork W2008154746 @default.
• W4384131508 hasRelatedWork W2082027006 @default.
• W4384131508 hasRelatedWork W2139665624 @default.
• W4384131508 hasRelatedWork W2331744132 @default.
• W4384131508 hasRelatedWork W2469878105 @default.
• W4384131508 hasRelatedWork W4254315070 @default.
• W4384131508 hasRelatedWork W566719283 @default.
• W4384131508 isParatext "false" @default.
• W4384131508 isRetracted "false" @default.
• W4384131508 workType "dissertation" @default.